Analyst Ratings For Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)
Today, HC Wainwright reiterated its Buy rating on Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) with a price target of $313.00.
There are 8 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) is Buy with a consensus target price of $262.6250 per share, a potential 132.12% upside.
Some recent analyst ratings include
- 12/12/2018-Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) had its Buy rating reiterated by HC Wainwright with a $313.00 price target
- 12/11/2018-Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has coverage initiated with a Neutral rating and $124.00 price target
- 11/19/2018-Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) gets downgraded to Underperform by Raymond James
- 11/16/2018-Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) gets upgraded to Outperform by Evercore ISI with a price target of $250.00
- 11/7/2018-Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) had its Buy rating reiterated by Cowen
- On 11/19/2018 Fred B Craves, Director, bought 2,000 with an average share price of $124.69 per share and the total transaction amounting to $249,380.00.
- On 11/19/2018 Paul A Friedman, CEO, bought 4,000 with an average share price of $124.00 per share and the total transaction amounting to $496,000.00.
- On 6/11/2018 Bay City Capital Llc, Director, sold 280,000 with an average share price of $287.46 per share and the total transaction amounting to $80,488,800.00.
- On 6/11/2018 Marc R Schneebaum, CFO, sold 10,099 with an average share price of $287.46 per share and the total transaction amounting to $2,903,058.54.
- On 6/11/2018 Rebecca Taub, Insider, sold 73,526 with an average share price of $287.46 per share and the total transaction amounting to $21,135,783.96.
- On 8/23/2017 Richard S Levy, Director, bought 2,000 with an average share price of $16.12 per share and the total transaction amounting to $32,240.00.
- On 8/22/2017 Richard S Levy, Director, bought 3,550 with an average share price of $16.12 per share and the total transaction amounting to $57,226.00.
About Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Recent Trading Activity for Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)
Shares of Madrigal Pharmaceuticals Inc closed the previous trading session at 111,91 −2,72 2,37 % with shares trading hands.